Shanghai ZJ Bio-Tech Co., Ltd.

Symbol: 688317.SS




Market price today

  • -22.8806

    P/E Ratio

  • -3.7753

    PEG Ratio

  • 2.96B

    MRK Cap

  • 0.08%

    DIV Yield

Shanghai ZJ Bio-Tech Co., Ltd. (688317-SS) Stock Price & Analysis

Shares Outstanding


Gross Profit Margin


Operating Profit Margin


Net Profit Margin


Return on Assets


Return on Equity


Return on Capital Employed


Company general description and statistics

Sector: Healthcare
Industry: Biotechnology
CEO:Ms. Weiqin Ni
Full-time employees:435
Address:Building 26

Shanghai ZJ Bio-Tech Co., Ltd. engages in the research and development, production, and sale of molecular genetic diagnostic reagents, and instruments and equipment in China. The company was founded in 2005 and is based in Shanghai, China.

General Outlook

In simple terms, Shanghai ZJ Bio-Tech Co., Ltd. has 192.158 M shares that people are buying and selling right now. When we look at how much money they make before expenses, they keep 0.719% as profit. This shows they're good at controlling costs and are financially stable. Their operating profit, which is money made from regular business activities, is -0.548%. This means they run their business efficiently. Lastly, after paying all their bills, they still have a profit of -0.472%. This tells us they're good at keeping money after all costs.

Return on Investments

The company's asset efficiency, represented by a robust -0.031% return, is a testament to Shanghai ZJ Bio-Tech Co., Ltd.'s adeptness in optimizing resource deployment. Shanghai ZJ Bio-Tech Co., Ltd.'s utilization of its assets to generate profits is strikingly evident through a noteworthy return on equity of -0.032%. Furthermore, the proficiency of Shanghai ZJ Bio-Tech Co., Ltd. in capital utilization is underscored by a remarkable -0.038% return on capital employed.

Stock Prices

Shanghai ZJ Bio-Tech Co., Ltd.'s stock prices have been subject to undulating patterns. The peak stock value during this interval surged to $16.08, while its low point bottomed out at $15.86. This variance in figures offers investors a lucid insight into the roller-coaster ride that is Shanghai ZJ Bio-Tech Co., Ltd.'s stock market.

Liquidity Ratios

Analyzing 688317.SS liquidity ratios reveals its financial health of the firm. The current ratio of 1595.74% gauges short-term asset coverage for liabilities. The quick ratio (1365.36%) assesses immediate liquidity, while the cash ratio (1293.76%) indicates cash reserves.

Current Ratio1595.74%
Quick Ratio1365.36%
Cash Ratio1293.76%

Profitability Ratios

688317.SS profitability indicators offer a lens into its earnings landscape. A pretax profit margin of -57.41% underscores its earnings before tax deductions. The effective tax rate stands at 17.71%, revealing its tax efficiency. The net income per EBT, 82.29%, and the EBT per EBIT, 104.69%, provide insights into its earnings hierarchy. Lastly, with an EBIT per revenue ratio of -54.84%, we grasp its operational profitability.

Pretax Profit Margin-57.41%
Effective Tax Rate17.71%
Net Income per EBT82.29%
EBT per EBIT104.69%
EBIT per Revenue-54.84%

Operational Efficiency

Operational metrics shed light on its business agility. With an operating cycle of 15.96, it details the span from stock purchase to revenue. The 14 days it takes to settle debts showcases its creditor relations. Meanwhile, a 13 cash conversion cycle and 166.95% receivables turnover rate reflect its cash flow efficiency and credit management, respectively.

Days of Sales Outstanding1365
Days of Inventory Outstanding2200
Operating Cycle2418.15
Days of Payables Outstanding516
Cash Conversion Cycle1902
Receivables Turnover1.67
Payables Turnover0.71
Inventory Turnover0.17
Fixed Asset Turnover0.42
Asset Turnover0.06

Cash Flow Ratios

Peering into the cash flow metrics reveals liquidity and operational efficiency. The operating cash flow per share, 0.85, and free cash flow per share, 0.99, depict cash generation on a per-share basis. The cash per share value, 14.20, showcases liquidity position. A payout ratio of -1.78 highlights the portion of earnings distributed as dividends. Lastly, the operating cash flow sales ratio, 0.60, offers insight into cash flow relative to sales.

Operating Cash Flow per Share0.85
Free Cash Flow per Share0.99
Cash per Share14.20
Payout Ratio-1.78
Operating Cash Flow Sales Ratio0.60
Free Cash Flow to Operating Cash Flow Ratio1.16
Cash Flow Coverage Ratio27.75
Short Term Coverage Ratio194.80
Capital Expenditure Coverage Ratio6.28
Dividend Paid and Capex Coverage Ratio0.64

Debt and Leverage Ratios

Diving into debt and leverage metrics unveils the company's financial structure. The debt ratio, at 0.14%, highlights its total liabilities relative to assets. The long-term debt to capitalization, 0.13%, and total debt to capitalization, 0.15%, ratios shed light on its capital structure. An interest coverage of -598.12 indicates its ability to manage interest expenses.

Debt Ratio0.14%
Long Term Debt to Capitalization0.13%
Total Debt to Capitalization0.15%
Interest Coverage-598.12
Cash Flow to Debt Ratio27.75
Company Equity Multiplier1.06

Per Share Data

Speaking about the per share data offers a perceptive view of financial distribution. The revenue per share, 1.42, provides a glimpse into top-line earnings distributed across each share. Net income per share, -0.67, reflects the portion of profit attributed to each share.

Revenue Per Share1.42
Net Income Per Share-0.67

Growth Ratios

Delving into growth metrics provides a snapshot of financial expansion. The revenue growth rate, -88.21%, indicates top-line expansion, while the gross profit growth, -77.17%, reveals profitability trends. EBIT growth, -116.58%, and operating income growth, -116.58%, offer insights into operational profitability progression. The net income growth, -117.05%, showcases bottom-line expansion, and the EPS growth, -117.05%, measures the growth in earnings per share.

Revenue Growth-88.21%
Gross Profit Growth-77.17%
EBIT Growth-116.58%
Operating Income Growth-116.58%
Net Income Growth-117.05%
EPS Growth-117.05%
EPS Diluted Growth-117.05%
10-Year Revenue Growth per Share3.67%
5-Year Revenue Growth per Share-8.39%
3-Year Revenue Growth per Share-86.55%
10-Year Net Income Growth per Share-239.58%
5-Year Net Income Growth per Share-255.81%
3-Year Net Income Growth per Share-114.00%
R&D Expense Growth-100.00%
SGA Expenses Growth-100.00%

Valuation Ratios

Exploring the valuation ratios offers insights into perceived market value. The price to book value ratio, 0.74, and the price to book ratio, 0.74, reflect the market's valuation relative to the company's book value. The price to sales ratio, 10.74, provides a perspective on valuation in relation to sales. Ratios like price to free cash flows, 15.42, and price to operating cash flows, 17.99, gauge market valuation against cash flow metrics.

Price Book Value Ratio0.74
Price to Book Ratio0.74
Price to Sales Ratio10.74
Price Cash Flow Ratio17.99
Price Earnings to Growth Ratio-3.78
Enterprise Value Multiple-50.05
Price Fair Value0.74
Price to Operating Cash Flow Ratio17.99
Price to Free Cash Flows Ratio15.42
Earnings Yield-3.19%
Trusted project
“All information displayed on the site is verified. High quality project and financial performance”
Eugene Alexeev
NumFin Founder and investing enthusiast

Frequently Asked Question

How many company shares are outstanding in 2024?

There are stock number shares outstanding of Shanghai ZJ Bio-Tech Co., Ltd. (688317.SS) on the SHH in 2024.

What is P/E ratio of enterprise in 2024?

The current P/E ratio of enterprise is -22.881 in 2024.

What is the ticker symbol of Shanghai ZJ Bio-Tech Co., Ltd. stock?

The ticker symbol of Shanghai ZJ Bio-Tech Co., Ltd. stock is 688317.SS.

What is company IPO date?

IPO date of Shanghai ZJ Bio-Tech Co., Ltd. is 2021-01-18.

What is company current share price?

Current share price is 15.390 CNY.

What is stock market cap today?

The market cap of stock today is 2957306218.000.

What is PEG ratio in 2024?

The current -3.775 is -3.775 in 2024.

What is the number of employees in 2024?

In 2024 the company has 435.